Aftas orales refractarias en tratamiento con adalimumab y apremilast en paciente con enfermedad de Behçet. Informe de un caso / Refractory oral aftas in treatment with adalimumab and apremilast in patient with Behçet syndrome. A case report
O.F.I.L
; 32(1): 99-100, enero 2022. graf
Article
in Spanish
| IBECS
| ID: ibc-205740
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
La enfermedad de Behçet es un trastorno inflamatorio multisistémico que se manifiesta de forma muy variada a nivel cutáneo, especialmente en forma de aftas orales frecuentemente refractarias. Los tratamientos con utilidad en la sintomatología de esta patología, resultan poco específicos y poco efectivos; teniendo que recurrir a veces a tratamientos sistémicos, como los biológicos entre ellos, los anti-TNFα. Presentamos el caso de una paciente con enfermedad de Behçet, con aftas orales severas, recurrentes y refractarias a múltiples tratamientos. Actualmente, la paciente ha alcanzado la remisión clínica en tratamiento combinado de adalimumab y apremilast. (AU)
ABSTRACT
Behçets disease is a multisystemic inflammatory disorder that manifests itself in a variety of ways at the cutaneous level, especially in the form of oral thrush, very often very refractory. Treatments that are useful in the symptomatology of this pathology are not very specific and not very effective; sometimes it is necessary to resort to systemic treatments, such as biologi-cal ones among them, anti-TNFα.We present the case of a patient diagnosed with Behçets disease, with severe oral aphthae, very recurrent and refractory to multiple treatments. Currently, the patient has reached clinical remission in combined treatment of adalimumab and apremilast. (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Pathology
/
Skin Diseases
/
Adalimumab
Limits:
Humans
Language:
Spanish
Journal:
O.F.I.L
Year:
2022
Document type:
Article
Institution/Affiliation country:
Hospital General La Mancha-Centro/España